Actinium Pharmaceuticals Presents New Preclinical Data From Its ATNM-400 Across Non-Small Cell Lung Cancer At 39th Annual Congress Of European Association Of Nuclear Medicine

Loading news article.

Actinium Pharmaceuticals Presents New Preclinical Data From Its ATNM-400 Across Non-Small Cell Lung Cancer At 39th Annual Congress Of European Association Of Nuclear Medicine | WAPE

Actinium Pharmaceuticals Presents New Preclinical Data From Its ATNM-400 Across Non-Small Cell Lung Cancer At 39th Annual Congress Of European Association Of Nuclear Medicine

Article summary

Related companies

Analyzed by WAPE AI.

Comments —